Bought a Generic Drug Years Ago? Check This $96 Million Settlement Before March 8

A multistate generic-drug settlement has a March 8, 2027 claim deadline. Check the covered drugs, 2009-2019 purchase window and eligibility before filing.

By James Park ·

People who bought certain generic prescription drugs from May 2009 through December 2019 may be eligible for compensation from multistate antitrust settlements. The claim deadline is March 8, 2027, according to the New York attorney general. Coverage depends on the particular drug, purchase period and the official settlement rules; buying any generic medicine is not enough.

New York and Connecticut attorneys general describe settlements totaling approximately $96 million with several drug manufacturers. Connecticut says a federal court granted preliminary approval to a plan for distributing consumer funds. Preliminary approval and an open claims window do not mean a particular person will receive a specific payment. The individual amount depends on valid claims and the settlement process.

To check eligibility, use the official settlement website linked from a state attorney general's announcement and review the covered-drug list and instructions. New York's announcement directs consumers to AGGenericDrugs.com. Do not enter prescription or payment information into a lookalike site reached through an unsolicited message. The state notices also give a telephone contact for questions.

The purchase window is long enough that receipts may be hard to find. Read the administrator's actual proof requirements before assuming a claim is impossible or guaranteed. A pharmacist's statement, insurance record or old receipt may help reconstruct a purchase, but the administrator decides whether evidence satisfies the settlement terms. This claim is separate from disputing a current medical bill; Financialist's medical-debt guide explains that other process.

Original sources

Related Financialist guides

About the writer

James Park · Business & Finance Desk

James tracks business litigation and intellectual property disputes. His beat covers SEC enforcement, antitrust actions, bankruptcy proceedings, and corporate governance cases.

LAWS.com author profile

News is not personalized legal or financial advice.